Table 3.
Kaplan‐Meier analysis of time to clinical stabilisation from commencement of combination treatment for 68 patients given the standard combination therapy
| Characteristics at commencement of combination treatment | Group | No. patients (n = 68) | Time (days) to clinical stabilization (median ± SE) | P‐value* |
|---|---|---|---|---|
| Age | < 41 | 32 | 5.0 ± 3.5 | 0.0002 |
| ≥ 41 | 36 | 12.0 ± 2.9 | ||
| Gender | Male | 27 | 12.0 ± 2.5 | 0.0636 |
| Female | 41 | 7.0 ± 1.8 | ||
| Smoker (active/ex‐) | Yes | 8 | 12.0 ± 7.8 | 0.8846 |
| No | 60 | 8.0 ± 1.1 | ||
| Diabetes mellitus | Yes | 8 | 24.0 ± 9.0 | 0.0050 |
| No | 60 | 8.0 ± 1.1 | ||
| Requirement for O2 supplementation | Yes | 21 | 12.0 ± 2.9 | 0.0965 |
| No | 47 | 7.0 ± 2.3 | ||
| Neutrophil count (× 109/L) | < 3.65 | 34 | 7.0 ± 2.5 | 0.0690 |
| ≥ 3.65 | 34 | 10.0 ± 3.4 | ||
| Lymphocyte count (× 109/L) | < 0.78 | 34 | 8.0 ± 2.1 | 0.9794 |
| ≥ 0.78 | 34 | 8.0 ± 1.3 | ||
| Platelet count (× 109/L) | < 158 | 33 | 10.0 ± 2.9 | 0.7846 |
| ≥ 158 | 35 | 8.0 ± 1.4 | ||
| Creatinine (µmol/L) | < 77 | 34 | 6.0 ± 1.8 | 0.0363 |
| ≥ 77 | 34 | 11.0 ± 1.9 | ||
| Alanine aminotransferase (IU/L) | < 31 | 34 | 7.0 ± 2.2 | 0.1013 |
| ≥ 31 | 34 | 9.0 ± 2.3 | ||
| Creatine kinase (IU/L) | < 93 | 34 | 7.0 ± 1.5 | 0.3040 |
| ≥ 93 | 34 | 10.0 ± 1.6 | ||
| Lactate dehydrogenase (IU/L) | < 262 | 34 | 7.0 ± 2.3 | 0.1096 |
| ≥ 262 | 34 | 12.0 ± 2.8 | ||
| CXR score | < 8.5 | 32 | 7.0 ± 2.4 | 0.0383 |
| ≥ 8.5 | 36 | 12.0 ± 2.9 |
† Log‐rank test.